Crizotinib is more effective than standard chemotherapy in the treatment of ALK-positive advanced lung cancer

Crizotinib is more effective than standard chemotherapy in the treatment of positive advanced lung cancer

Previous single-group studies have shown that chromosomal rearrangements of the anaplastic lymphoma kinase gene are associated with oral tyrosine kinase inhibitor-targeted drugs. Zotinib was associated with significant clinical responses. However, it remains unclear whether crizotinib is more effective than standard chemotherapy. Doctors at the Boston General Hospital Cancer Center and others conducted in-depth research and found that for patients with advanced non-small cell lung cancer whose genes have been rearranged after previous treatment, crizotinib is more effective than standard chemotherapy. Relevant papers were published in the online edition of the authoritative international magazine.
Researchers conducted a phase 1 open-label trial to compare the efficacy of chemotherapy with crizotinib in patients with locally advanced or metastatic lung cancer who had received a single platinum-based regimen. Patients were randomly assigned to receive oral crizotinib ( ) twice daily or weekly intravenous chemotherapy with pemetrexed (per square meter of body surface) or docetaxel (per square meter of body surface). Patients in the chemotherapy group who progressed were crossed over to the crizotinib treatment group as part of an independent study. The primary endpoint of the trial is progression-free survival.
The results showed that the median progression-free survival time in the crizotinib treatment group and the chemotherapy group were months and months respectively (the hazard ratio of progression or death in the crizotinib group was % confidence interval [], to). The response rate in the crizotinib treatment group was % (%, ), compared with % (%, ) () in the chemotherapy group. An interim analysis of overall survival showed no significant difference between the groups (hazard ratio, %, ) in the crizotinib group. Common adverse reactions in the crizotinib group were visual impairment, gastrointestinal side effects, and increased liver aminotransferase levels, while common adverse reactions in the chemotherapy group were fatigue, hair loss, and dyspnea. Patients reported more relief from lung cancer symptoms and an improvement in their overall quality of life in the crizotinib group compared with those in the chemotherapy group.
The researchers concluded that treatment with crizotinib is superior to standard chemotherapy for patients with advanced non-small cell lung cancer who have rearranged genes after previous treatment.

Address: Zhongguancun Building, Beisihuan Middle Road, Haidian District, Beijing
Company name: Beijing Mingkang Trading Co., Ltd.
Telephone:
Number:
Contact Person: Miss Chen